Publisher
Springer Science and Business Media LLC
Subject
Emergency Medicine,Internal Medicine
Reference10 articles.
1. Lemtrada: European Public Assessment Report – Product Information, European Medicines Agency. (2013) https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_en-0.pdf. Accessed 19 Oct 2021
2. Buckstein R, Fraser G, Cheung M, Kukreti V, Kuruvilla J, Imrie K et al (2016) Alemtuzumab and CHOP chemotherapy for the treatment of aggressive histology peripheral T cell lymphomas: a multi-center phase I study. Clin Lymphoma, Myeloma Leuk 16(1):18-28.e4. https://doi.org/10.1016/j.clml.2015.11.008
3. Wulf GG, Altmann B, Ziepert M, D’Amore F, Held G, Greil R et al (2021) Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia 35(1):143–155
4. Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ et al (2019) Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler J 25(12):1605–17. https://doi.org/10.1177/1352458518796675
5. Geisler CH, van t’Veer MB, Jurlander J, Walewski J, Tjønnfjord G, Itälä Remes M et al (2014) Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 123(21):3255–62